Compare AbCellera Biologics Inc (ABCL) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Taskus Inc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Taskus Inc trades at $5.13 (market cap $475.98M). The key difference: AbCellera Biologics Inc is far larger — about 4.9× Taskus Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | TASK | |
|---|---|---|
Market Cap | $2.35B | $475.98M |
Sector | Health | Technology |
52-Week High | $8.12 | $18.21 |
52-Week Low | $2.78 | $4.57 |
Enterprise Value | $1.99B | $871.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TaskUs trades at $5.19, up 3.18% today, with a bearish technical signal despite strong fundamentals including a P/E of 4.59 and net income margin of 8.7%. Recent Q1 2026 earnings missed expectations, but revenue reached $1.18B in 2025. The company appointed a new CFO in June 2026 and reported growing interest in robotaxi services, indicating strategic positioning in digital customer experience.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. Risks include recent earnings volatility and competitive pressures in outsourcing services. Analyst sentiment is mixed with 55% buy ratings, suggesting cautious optimism amid near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
